Clinical Trial Results:
A PHASE 2b, RANDOMIZED, MULTI-CENTER, ACTIVE-CONTROLLED,
OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ALBUFERON (RECOMBINANT HUMAN ALBUMIN-INTERFERON ALFA FUSION PROTEIN) IN COMBINATION WITH RIBAVIRIN IN INTERFERON ALFA NAIVE SUBJECTS WITH CHRONIC HEPATITIS C GENOTYPE 1
Summary
|
|
EudraCT number |
2005-000867-24 |
Trial protocol |
DE CZ |
Global completion date |
10 May 2007
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
27 Jan 2019
|
First version publication date |
27 Jan 2019
|
Other versions |
|
Summary report(s) |
gsk-alfr-hc-04-synopsis-redact |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.